KRAS and neoplasm: While two patients (patients 2 and 3) lacked molecular intra-patient heterogeneity before immunotherapy, harboring only a KRAS mutation or no evident driver mutation, the primary tumor of patient 1 showed a heterogeneous molecular profile with several different clones and different driver mutations.